ArticleAnnals of surgical oncology2023
The Role of Cryoablation in Breast Cancer Beyond the Oncologic Control: COST and Breast-Q Patient-Reported Outcomes.
Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Assessing Financial Toxicity in Cancer: A Global Systematic Review and Meta-Analysis Using an Asset Framework.Cancer medicine · 2026Pooled it
- Evaluation of financial toxicity and associated factors in female patients with breast cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- Cryoablation for early-stage invasive breast cancer: pathologic and imaging outcomes from the prospective FIRST trial.Breast cancer research : BCR · 2026Trial
- Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial.JAMA network open · 2023Trial
- Cryoablation in Early-Stage Breast Cancer: A Systematic Review of Efficacy, Safety and Oncologic Outcomes.Cancers · 2026Review
- Cryoablation for Low-Risk Small Breast Cancer: When Less Is More for Patients and Payers.Cardiovascular and interventional radiology · 2026Article
- Cryoablation Versus Breast-Conserving Surgery for Early-Stage, Low-Risk Breast Cancer ≤ 1.5 cm: A Cost-Effectiveness Analysis.Cardiovascular and interventional radiology · 2026Article
- Immunomodulatory effect of ultrasound-guided cryoablation in early breast cancer: pilot study on blood and surgical samples.European radiology experimental · 2025Article
- Review
- Post-treatment patient satisfaction in early-stage breast cancer: comparison of cryoablation versus breast conservation therapy using BREAST-Q.Gland surgery · 2025Article
- Cryoablation for breast cancer: a narrative review of advances, clinical applications, and future challenges.Translational cancer research · 2025Review
- The Role of Molecular Profiling in De-Escalation of Toxic Therapy in Breast Cancer.International journal of molecular sciences · 2025Review
- Imaging in Interventional Radiology: Breast Cryoablation.Seminars in interventional radiology · 2025Review
- Cryoablation in the treatment of early breast cancer: a comprehensive analysis.Frontiers in oncology · 2025Review
- Ultrasound-guided cryoablation of early breast cancer: safety, technical efficacy, patients' satisfaction, and outcome prediction with MRI/CEM: a pilot case-control study.European radiology experimental · 2024Article
- Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence.Annals of surgical oncology · 2024Article
- Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients.The British journal of radiology · 2024Article
- Cancer cost-related subjective financial distress among breast cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan.Breast cancer (Tokyo, Japan) · 2024Article
- Role of Interventional Radiology in Managing Primary and Metastatic Breast Cancer.Seminars in interventional radiology · 2024Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryoablation has been established as a minimally invasive alternative to resection of early-stage breast cancer; however, there are no data on the cost and impact on patients' financial, psychosocial, sexual, physical, and cosmetic outcomes utilizing this approach. This study compares cost-effectiveness and patient-reported quality-of-life factors in cryoablation versus resection.
methodsWomen with early-stage, low-risk infiltrating ductal carcinomas ≤ 1.5 cm underwent cryoablation or resection. Adjuvant therapy was provided according to tumor board recommendations. Direct and indirect costs were tracked for both groups. Financial toxicity and well-being outcome were measured by administering the Comprehensive Score of Financial Toxicity (COST) and BREAST-Q surveys, respectively, at 6-month follow-up.
resultsOf the 34 eligible patients, 14 (41.1%) consented for cryoablation and 20 (58.8%) underwent resection. The median (centile) (range) follow-up was 35.0 (21.3) (15-50) months for cryoablation vs. 25 (20.8) (17-50) months for resection [p = 0.6479]. Mean (standard deviation) cost of care for cryoablation versus resection was $2221.70 (615.70) versus $16,896.50 (1332.40) [p < 0.0001], and median financial well-being scores for the cryoablation versus resection groups were 38.0 (34.5, 40.0) versus 10 (5.3, 14.0) [p < 0.0001]. Poor financial well-being was directly correlated with the cost of care [p < 0.0001]. Median psychosocial well-being scores were similar across both groups, however the cryoablation group had higher scores for physical [100 (100, 100) vs. 89 (79, 100); p = 0.0141], sexual [100 (91, 100) vs. 91 (87.5, 91); p = 0.0079], and cosmetic [100 (100, 100) vs. 88 (88, 100); p = 0.0171] outcomes.
conclusionCryoablation offers a cost-effective and quality-of-life advantage compared with resection for early-stage, low-risk breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.